An open-label, single-dose, randomized, 4-period, crossover, bioequivalence study of 3 new formulations of Premarin /MPA 0.625 mg/2.5 mg compared with reference formulation of Premarin/MPA in healthy postmenopausal women.
Phase of Trial: Phase I
Latest Information Update: 03 Feb 2009
At a glance
- Drugs Conjugated estrogens/medroxyprogesterone (Primary)
- Indications Menopausal syndrome
- Focus Pharmacokinetics
- Sponsors Wyeth
- 03 Feb 2009 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 29 Mar 2008 New trial record.